Details Basic Details Status Ongoing Last Updated Monday, August 26, 2024 Original Posting Date Tuesday, April 23, 2024 Health Outcome(s) utilization Purpose Drug Utilization Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR No Analytic Code Link(s) (1) Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Interrupted Time Series Analysis Result(s) (1) Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Updated Interrupted Time Series Analysis Regulatory Link(s) (2) Hydrochlorothiazide & Non-Melanoma Skin Cancer FDA Labeling Change: Hydrochlorothiazide and Non-Melanoma Skin Cancer